Hem › Metastaserande cancer › New Mexico
Kliniska studier för Metastaserande cancer i New Mexico
13 studier för Metastaserande cancer söker deltagare vid platser i New Mexico.
Städer i New Mexico
Officiell studietext (engelska)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of New Mexico Cancer Center, Albuquerque
RekryterarFas 2
Alla åldrar · Alla kön · Uppdaterad 2 okt. 2026 · NCT05564377Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07222800Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
- CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07222566A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06103864Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- New Mexico Oncology Hematology Consultants, Albuquerque
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07028489A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Optimum Clinical Research Group, Albuquerque
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07213804A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT06119581Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Albuquerque
RekryterarFas 3
Ålder 18 och äldre · Kvinnor · Uppdaterad 29 juli 2026 · NCT07044336A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Christus St Vincent Regional Medical Center, Santa Fe
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 15 juli 2026 · NCT06657144A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- New Mexico Oncology Hematology Consultants Ltd, Albuquerque
RekryterarFas 1
Ålder 18 och äldre · Män · Uppdaterad 4 feb. 2026 · NCT04729114VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Presbyterian Kaseman Hospital (site 208), Albuquerque
RekryterarFas 1/2
Ålder 18 till 80 · Alla kön · Uppdaterad 11 dec. 2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.